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Abstract: Uterine fibroids are the commonest uterine benign tumors. A potential 
mechanism of malignant transformation from leiomyomas to leiomyosarcomas has been 
described. Tyrosine phosphorylation is a key mechanism that controls biological functions, 
such as proliferation and cell differentiation. The aim of the current study was to evaluate 
the phosphorylation of epithelial growth factor-receptor (EGFR) in normal myometrium, 
uterine myomas and uterine leiomyosarcomas. Formalin-fixed paraffin-embedded tissue 
samples from normal myometrium, leiomyomas and leiomyosarcomas were studied. 
Samples were immunohistochemically (IHC) assessed using the anti-EGFR phosphorylation 
of Y845 (pEGFR-Y845) and anti-pEGFR-Y1173 phosphorylation-specific antibodies. IHC 
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staining was evaluated using a semiquantitative score. The expression of pEGFR-Y845 
was significantly upregulated in leiomyosarcomas (p < 0.001) compared to leiomyomas 
and normal myometrium. In contrast, pEGFR-Y1173 did not differ significantly between 
the three groups of the study. Correlation analysis revealed an overall positive correlation 
between pEGFR Y845 and mucin 1 (MUC1). Further subgroup analysis within the tumoral 
group (myomas and leiomyosarcomas) revealed an additional negative correlation between 
pEGFR Y845 and galectin-3 (gal-3) staining. On the contrary no significant correlation 
was noted within the non-tumoral group. An upregulated EGFR phosphorylation of Y845 in 
leiomyosarcomas compared to leiomyomas implicates EGFR activation at this special 
receptor site. Due to these pEGFR-Y845 variations, it can be postulated that MUC1 
interacts with it, whereas gal-3 seems to be cleaved from Y845 phosphorylated  
EGFR. Further research on this field could focus on differences in EGFR pathways as a 
potentially advantageous diagnostic tool for investigation of benign and malignant signal 
transduction processes. 
Keywords: myometrium; leiomyoma; leiomyosarcoma; phosphorylation; EGFR;  
tyrosine kinase 
 
1. Introduction 
Uterine leiomyomas are common pelvic tumors of women of reproductive age [1,2]. Differences 
occur by race and age. Afro American women have a greater burden regarding fibroids [3–5] 
compared to Caucasian women. Previous studies have focused on leiomyosarcomas and their 
origination from either pre-existing leiomyomas or their de novo development [6]. Malignant 
transformation of leiomyomas into leiomyosarcomas seems to be rare, however still debated in 
literature [7,8]. In addition, Mittal et al. demonstrated that leiomyosarcomas can arise from 
leiomyoma-like areas [9]. Histopathological differentiation between leiomyoma, myoma with 
pseudosarcomatous features and leiomyosarcoma can be exceedingly difficult [10]. The biology of the 
development of these mesenchymal malignant tumors is not well understood. 
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase, a member of the  
ErbB-family and a regulator of various cellular processes, including cell survival, differentiation, 
migration and cell growth [11]. The EGFR is implicated in pathological processes, such as 
oncogenesis, and is linked with a poor prognosis in several epithelial carcinomas [12]. Inhibition of 
uncontrolled EGFR expression improved treatment of malignant diseases, such as breast and lung 
cancers [13]. The investigation of EGFR and its signaling pathway is, therefore, important in research 
concerning the tumor biology of this entity. 
There is evidence that mucin-1 (MUC1) has a regulatory function in the trafficking and nuclear 
activity of EGFR [12]. Recently, we demonstrated that epithelial mucin-1 (MUC1) was upregulated in 
leiomyomas and leiomyosarcomas compared to normal myometrium [14]. Interestingly, it was also 
shown that MUC-1 and EGFR may be regulated by galectin-3 in pancreatic carcinoma [15]. To this 
direction, Gal-3 has also been reported to interact with MUC1 and EGFR, acting as a bridge between 
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MUC1 and EGFR [16]. Since EGFR and MUC1 are now considered ligands for Gal-3, it could be 
hypothesized that these three molecules could form a regulatory network, necessitating the study of 
this molecule in parallel, rather than separately. 
EGFR phosphorylation is regulated by dephosphorylation and transphosphorylation of receptors by 
tyrosine phosphatases. 
Phosphorylation of EGFR on tyrosine 845 is accompanied with activation of this receptor tyrosine 
kinase. It is known to be responsible for oncogenetic processes [11] and is required for the 
transactivation of EGFR [17,18]. Furthermore, phenylalanine substitution of Y845 (Y845F) was found 
to inhibit EGF-induced DNA synthesis, making Y845 a potential target in oncological treatment 
decisions [11]. 
The Y1173 EGFR phosphorylation was investigated recently. An interaction of this 
phosphorylation site with the EGFR has been described, supporting it as a promising therapeutical 
target in breast and lung cancer [13]. 
The role of EGFR phosphorylation has not been investigated so far in leiomyomas and 
leiomyosarcomas. Since galectins have been reported as being involved in tumor development, 
investigation of their interaction with phosphorylated EGFR (pEGFR)-Y845 and -Y1173 may also  
be important. 
The aim of this study was to evaluate differences in the EGFR activation by phosphorylation in 
myomas and leiomyosarcomas. We additionally aimed to analyze potential correlations between the 
EGFR phosphorylations under study and the expressions of MUC1 and Gal-3. 
2. Results and Discussion 
2.1. EGFR-Y845 
In normal myometrium, pEGFR-Y845 staining was either absent or weak (mean International 
Remmele Score (IRS) = 0.73 ± 0.30). A total of 17 patients with myomas were investigated for 
pEGFR-Y845 staining. Only two cases (11.7%) were positive for the phosphorylated EGFR in this 
position, yielding a mean IRS = 0.47 ± 0.36 (Figure 1). In contrast, all cases with leiomyosarcomas 
showed a strong staining, with a mean IRS = 5.22 ± 0.84 (Figure 1), differing highly significantly both 
from myometrium (p < 0.001) and myoma (p < 0.001) pEGFR-Y845 expression. 
2.2. EGFR-Y1173 
In normal myometrium, pEGFR-Y1173 staining was found to be moderate  
(mean IRS = 6.66 ± 0.42). A total of 21 patients with myomas were investigated for pEGFR-Y1173 
staining. In all cases, we identified a medium to strong reactivity for pEGFR-Y1173 in myomas  
(mean IRS = 6.52 ± 0.58) (Figure 1). All cases of leiomyosarcomas also showed a comparable 
pEGFR-Y1173 reactivity (mean IRS = 6.66 ± 0.66) (Figure 1). None of the groups differed 
significantly from the others in terms of pEGFR-Y1173 expression. 
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Figure 1. Representative microphotographs of the molecules currently studied in 
myometrium, myoma and leiomyosarcoma cases. As shown, both in the microphotographs 
and in the graph, the epithelial growth factor-receptor (EGFR) phosphorylation of Y845 is 
significantly more abundant in leiomyosarcomas compared to myomas and normal 
endometrium (p < 0.05). Positive control (breast cancer) and negative control 
(leiomyosarcoma stained with IgG isotype control serum). Bar = 100 μm. 
 
2.3. Correlation Analysis 
In order to perform the so described correlation analysis, the corresponding data for the patients 
participating in the current study (being a part of a previous study published by our group [14] 
regarding MUC1 and Gal-3 expression, were retrieved. Initial correlation analysis by merging the 
tumoral (myoma and leiomyosarcoma) and the non-tumoral (myometrium) cases revealed a positive 
correlation between the EGFR phosphorylation of Y845 (pEGFR-Y845) and MUC1 (Spearman r,  
p = 0.009). Further subgroup analysis within the tumoral cases revealed that the EGFR Y845  
(pEGFR-Y845) correlated positively with the MUC1 expression (Spearman r, p = 0.003). A significant 
negative correlation could be also demonstrated between pEGFR-Y845 phosphorylation and Gal-3 
expression (Spearman r, p = 0.010). Correlation analysis did not reveal any significant correlation 
within the non-tumoral group. 
The activation of EGFR by the phosphorylation of Y1173 (pEGFR-Y1173) did not correlate 
significantly neither with pEGFR-Y845 (p = 0.827) nor with MUC1 (p = 0.195)/Gal-3 (p = 0.15) stainings. 
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2.4. Discussion 
The role of EGFR along with vascular endothelial growth factor (VEGF) were already investigated 
in leiomyomas and leiomyosarcomas [19]. It was concluded that angiogenic growth factors seem to 
play an important role in the induction of malignant transformation of leiomyosarcomas. The 
overexpression of EGFR in uterine leiomyosarcomas compared to uterine myomas was also 
demonstrated in mice [20]. Sato et al. demonstrated an EGFR overexpression in human soft tissue 
sarcomas. A total of 73% of leiomyosarcomas had a positive EGFR staining, whereas lower expression 
was described in liposarcomas [21]. Recently, the activation of EGFR pathways—as this was shown 
by pEGFR-Y1173 staining—in leiomyosarcoma cases was reported [22]. Treatment of testicular 
leiomyosarcoma cells with the EGFR inhibitor, gefitinib, combined with vincristine succeeded in 
reducing tumor size by increasing the tumor cell apoptotic rate [22]. Additionally, an elevated  
pEGFR-Y1173 activation was shown in leiomyosarcoma cases compared to myometrium cases, which 
served as controls [22]. Our results are in partial concordance with these findings. We could verify the 
moderate to strong expression of pEGFR-Y1173 in leiomyosarcoma cases. However, in our small 
series, pEGFR-Y1173 was found in comparable rates in both myomas/leiomyosarcomas, as well as in 
normal myometrium. The disagreement regarding the normal myometrium between our results and the 
results presented by Sette et al. [22] highlights the necessity of a large case series, which will clarify 
the role of the pEGFR-Y1173 in tumorigenesis. After all, both the myometrium samples presented by 
us and by Sette et al. are quite small. Thus, conclusions are to be made with caution. 
To the best of our knowledge, this is the first time that pEGFR-Y845 activation was demonstrated 
in leiomyosarcoma. Interestingly, this upregulation was characteristic only for leiomyosarcomas, since 
both myomas and normal myometrium presented with weak immunoreactivity. This finding may 
indicate a role for pEGFR-Y845 in the transformation of both myometrium and myomas to 
leiomyosarcoma. This, in turn, could support the existing theories of leiomyosarcoma tumorigenesis, 
claiming that this malignancy may initiate either de novo or from an existing myoma. Although  
we could not show a differential pEGFR-Y1173 immunoreactivity, by combining the results of  
Sette et al. [22] with the ones presented herein, we can hypothesize that EGFR activation by 
phosphorylation on multiple sites could contribute to leiomyosarcoma tumorigenesis and 
chemoresistance; thus, such phosphorylation sites could be major candidates for designing efficient 
interventions with potential clinical impact. 
Nonetheless, the current findings are more supportive for pEGFR-Y845 to play a role in EGFR 
activation, at least in uterine leiomyosarcoma. The phosphorylation of Y845 on EGFR was previously 
reported to be an important regulator in oncogenetic pathways by binding proteins, such as  
cytochrome c oxidase II [11]. Additionally, EGFR Y845 phosphorylation has been shown to be in a 
crosstalk with c-Src, inducing proliferation of breast cancer cells [23]. This interaction between 
pEGFR-Y845 and c-Src has been reported to be important in proliferation and tumorigenesis [24]. 
Herein, a positive correlation between pEGFR-Y845 and MUC1 was demonstrated. A regulatory 
function of MUC1 on EGFR was already described by Bitler et al. They reported that the presence  
of MUC1 results in significant co-localization of EGFR and influences the association of EGFR with 
transcriptionally active promoter regions [12]. Supporting our results, Li et al. reported the co-expression 
of both MUC1 and EGFR; this further strengthens the herein presented MUC1/pEGFR-Y845 
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correlation [25]. No correlation was highlighted between Y1173 and any of the rest of the molecules of 
the current study. Nevertheless, it is an alternative way of EGFR activation being related to oncogenic 
pathways; activated c-Src phosphorylates the EGFR at Y1173 [26]. 
Interestingly, in tumoral cases (myomas and leiomyosarcomas), but not in myometrium,  
pEGFR-Y845 proved to correlate negatively with Gal-3. This significant negative correlation could 
imply a possible downregulation of Gal-3 by pEGFR-Y845, with an additional promoting result in 
oncogenesis. This hypothesis could be further supported by the fact that loss of Gal-3 is reported to be 
associated with the progression and invasive potential of metastatic cells [27]. Reduction in Gal-3 has 
also been demonstrated in ovarian carcinogenesis, since Gal-3 immunostaining was found to decrease 
significantly in the transition from cystadenomas and serous borderline tumors to carcinomas [28]. 
Thus, the negative correlation between pEGFR-Y845 and Gal-3, shown herein in tumoral cases, 
highlights a potential EGFR regulation of galectin-3, this being possibly important in the 
transformation of myomas to leiomyosarcomas. 
Our findings, although clearly supporting a phospho-EGFR-Y845/MUC1/Gal-3 correlation, should 
be taken with caution. Larger samples of uterine leiomyosarcomas may be necessary to clarify the 
extent to which phospho-EGFR-Y845 contributes to uterine leiomyosarcoma transformation. Further 
studies are also needed in order to assess the role of this phosphorylation in clinical outcomes (disease 
free and overall survival). 
3. Experimental Section 
3.1. Study Population 
Tissue samples from normal myometrium, leiomyomas or leiosarcomas were obtained  
from the archives of the First Department of Obstetrics and Gynecology, Innenstadt Campus,  
Ludwig-Maximilian-University Munich, Germany. A total of 30 women with uterine myomas (n = 21) 
or leiomyosarcomas (n = 9) were included in the study. Another 15 cases of women that underwent 
hysterectomy due to benign endometrial pathology were included as controls (normal myometrium). 
The EGFR phosphorylation of Y845 (pEGFR-Y845) was investigated in 15 cases of normal 
myometrium, in 17 cases of myomas and in 9 cases of leiomyosarcomas. The EGFR phosphorylation 
of Y1173 (pEGFR-Y1173) was investigated in 6 cases of normal myometrium, in 21 cases of myomas 
and in 9 cases of leiomyosarcomas. The institutional review board of the Ludwig-Maximilian-University 
Munich, Germany, approved the study, and all the patients gave their informed consent. 
3.2. Immunohistochemistry 
Formalin-fixed paraffin-embedded tissue sections were deparaffinized in xylol for 15 min, 
rehydrated in a descending series of alcohol (100%, 70% and 50%) and subjected to epitope retrieval 
for 10 min in a pressure cooker using sodium citrate buffer (pH 6.0) containing 0.1 M citric acid and 
0.1 M sodium citrate in distilled water. After cooling, the sections were washed twice in phosphate 
buffered saline solution (PBS). Non-specific binding of the primary antibodies was blocked by 
incubating the sections with diluted normal serum (10 mL PBS containing 150 µL horse serum; Vector 
Laboratories, Burlingame, CA, USA) for 20 min at room temperature. The sections were then 
Int. J. Mol. Sci. 2013, 14 4789 
 
 
incubated at room temperature for 60 min with the primary antibodies. The primary antibodies used 
along with their features are presented in Table 1. Reactivity was revealed using the appropriate 
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer’s 
protocol. Visualization was performed using substrate and the chromogen 3,3'-diaminobenzidine 
(DAB; Dako, Glostrup, Denmark) for 2 min. The sections were then counterstained with Mayer’s 
acidic hematoxylin and dehydrated in an ascending series of alcohol (70%–100%). After xylol 
treatment, the sections were covered. Negative controls were performed by replacing the primary 
antibody with the appropriate IgG isotype control serum. Breast cancer tissue sections were used as 
positive control. 
Table 1. Salient features of the antibodies used in the current study. 
Antibody Clone Isotype Concentration  Source 
pEGFR-Y845 polyclonal Rabbit IgG 1.0 mg/mL R & D Systems, USA 
pEGFR-Y1173 polyclonal Rabbit IgG 1.0 mg/mL  R & D Systems, USA 
Galectin-3 9C4 Mouse IgG 2.0 µg/mL Novocastra, UK 
Mucin-1 VU-4-H5 Mouse IgG1 6.8 µg/mL Invitrogen, USA 
The intensity and distribution patterns of specific immunohistochemical staining were evaluated 
using the semiquantitative International Remmele Score (IRS), as described elsewhere, to assess the 
expression pattern of other molecules, such as steroid receptors, glycodelin and MUC1 [29–31]. The 
IRS score was calculated by multiplication of the optical staining intensity (graded as 0 = no, 1 = weak,  
2 = moderate and 3 = strong staining) and the percentage of positively stained cells (0 = no staining,  
1 = <10% of cells, 2 = 11%–50% of cells, 3 = 51%–80% of cells and 4 = >81% of cells stained). The 
slides were scored by two observers by consensus. Sections were examined using a Leitz (Wetzlar, 
Germany) microscope equipped with a 3CCD color camera (JVC, Victor Company of Japan, 
Yokohama, Japan). 
3.3. Statistics 
The results were evaluated using the non-parametric Mann-Whitney-U test. The non-parametric 
Spearman correlation coefficient was used for estimating correlation between MUC1 and Gal-3 and 
the phosphorylations of EGFR (pEGFR-Y845 and pEGFR-Y1173) (IBM SPSS, New York, NY, 
USA). Significance was assumed at p < 0.05. 
4. Conclusions 
Therapeutic strategies, such as the use of trastuzumab and other tyrosine kinase inhibitors, have 
already been approved for targeted treatment of cancer. This targeted therapy is currently limited to 
certain cancers in clinical practice. The blockade of EGFR as an important therapeutical intervention 
alone and in combination with chemotherapy has already been investigated in soft tissue sarcomas 
(including uterine leiomyosarcomas) using in vitro and in vivo (animal model) experiments with 
promising results [32]. Our findings further support these results and highlight a role for EGFR and 
especially for the activation by phosphorylation of Y845, as far as uterine leiomyosarcoma is concerned. 
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